RecruitingNCT07266545
RNA patterns and antidepressant response in depression, including bipolarity
About this title
Read the official source — NCT07266545Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- RochesterSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 17, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- Mayo Clinic
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07266545
- Official title
Show the full official title
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Rochester
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Mayo Clinic, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Vortioxetine and Cariprazine (Augmentation Phase).
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
